Jonathan W. Ayers served as Chairman and Chief Executive Officer of IDEXX Laboratories from 2002 to 2019, a period during which he transformed the company from a $500 million niche player into a $2.5 billion global leader in veterinary diagnostics.

Before joining IDEXX, Ayers had a distinguished career in technology and healthcare. He served as President and CEO of MiniMed Inc., a leading diabetes management company, and held senior positions at Eli Lilly and Company.

Ayers' strategic vision for IDEXX centered on the "razor-razorblade" business model—placing diagnostic instruments in veterinary practices and generating recurring revenue from consumables and reference lab services. This approach created exceptional switching costs and customer loyalty.

Under his leadership, IDEXX developed breakthrough products including the Catalyst Dx chemistry analyzer and the SNAP rapid diagnostic tests, which revolutionized point-of-care veterinary diagnostics. He also oversaw the expansion of the company's reference laboratory network globally.

Ayers was known for his intense focus on innovation and customer service. He invested heavily in R&D, maintaining spending at approximately 10% of revenue—well above industry averages. This commitment to innovation helped IDEXX maintain its technological leadership and premium pricing.

His tenure saw IDEXX's stock price increase by over 2,000%, making it one of the best-performing healthcare stocks of the 2000s and 2010s.